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Vaccine Enterprise.
A. IntroductIon
The Global HIV Vaccine Enterprise convened a workshop in September 
2009 to discuss human and viral genetic variation and its impact on 
future directions for HIV vaccine research and development. The formi-
dable challenges presented by virus and host genetic variability are inter-
related and complicate vaccine development. HIV vaccine researchers 
need to develop innovative approaches that will facilitate addressing 
these questions in novel ways.
B. chAllenges And opportunItIes
host genetic Variability
Human genetic variability influences susceptibility to HIV-1 infection, 
rate of disease progression and immune responses to vaccination.
Resistance to infection. Many studies have identified individuals 
who remain uninfected after repeated exposure to HIV-1. The clearest 
and the best-understood mode of protection against HIV-1 infection 
results from deficiency in expression of the virus co-receptor CCR5 
as the result of a 32 base pair deletion in the coding sequence of the 
CCR5 gene1. However, only a subset of protected individuals carries 
the CCR5 deletion. Others appear to develop protective immune 
responses, elicited as the result of repeated exposure to HIV, leading 
to transient or locally contained infection, without becoming produc-
tively infected with the virus2–4.
HLA associations. Once infection has occurred, a number of genes 
are known to affect HIV-1 viral load and/or rate of disease progres-
sion with the MHC complex having the most profound influence5. 
Detailed HLA typing has revealed that several alleles are associated 
with lower viral set point or delayed progression to AIDS: B*5701, 
B*5703, B*5801, B*2705 and B*5101. The mechanisms underlying this 
phenomenon are not fully understood, but for the B27, B51 and B57/58 
families it is probable that HLA-restricted T cells play an important 
role by targeting conserved epitopes in the HIV-1 p24 protein6,7. 
Viruses can escape T cell recognition by mutation and subsequent 
selection, but this often incurs a fitness cost8–12. In contrast, rapid 
disease progression is associated with some subtypes of HLA B*35. 
The mechanism may involve a relatively high affinity interaction of 
peptide-MHC complexes with LILRB2, an HLA class I receptor on 
monocytes and dendritic cells, responsible for downregulation of den-
dritic cell function13. Genome-wide association studies (GWAS) have 
also identified a variant in HLA-C, the -35 SNP that is associated with 
lower viral load, although its mechanism of action is not clear14. Recent 
GWAS studies15–17, including a first study in an African American 
cohort18, have excluded the influence of many other genes previously 
proposed to influence the outcome of HIV-1 infection, rather than 
identifying further protective genes.
NK cell receptors. The killer immunoglobulin-like receptors 
(KIRs) are found on natural killer (NK) cells and a subset of T cells 
(KIR+CD8+). KIRs are either inhibitory or activating and have several 
allelic forms and gene copy number variability. They bind to class I 
HLA molecules focusing on the Bw4/6 region of the alpha-1 helix. 
KIR3DL1 and KIR3DS1 are associated with favorable control of HIV-1 
virus load or slow disease progression in individuals with the appro-
priate HLA Bw4 type19–22. These findings strongly implicate NK cells, 
and/or KIR+CD8+ T cells, in the control of HV-1 infection.
The importance of host genetics in vaccine studies may also be sig-
nificant. Host genetic variation might influence response to vaccina-
tion and thereby confound vaccine efficacy studies. This issue may 
become especially important in vaccine trials involving genetically 
diverse populations where there may be as yet undiscovered genetic 
variation that could affect clinical outcome.
hIV Variability and its sources
HIV-1 is one of the most genetically variable viruses known. Variation 
is fueled by an error-prone reverse transcriptase and magnified by 
frequent recombination events. From the time it entered the human 
population, HIV has diversified into multiple genetic subtypes, or 
clades, each with a distinct geographic distribution. Moreover, some 
inter-subtype recombinant forms of the virus have gained widespread 
prevalence and are therefore important targets of HIV vaccine devel-
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to increase fitness), suggesting that selection by the innate immune 
response also contributes to viral variation. Innate immune responses 
are the first to appear in acute HIV-1 infection, leading to activation 
and expansion of NK cells, dendritic cells and macrophages. The spe-
cific role of the innate immune response in viral containment in vivo 
remains poorly understood.
c. WAy ForWArd
The Working Group identified several priority areas that remain critical 
challenges on the path to a safe and effective HIV vaccine.
priority 1: create enabling environments that foster innovative, 
collaborative, and global approaches
Recent advances in sequencing technology provide an unprecedented 
opportunity for developing a detailed picture of both human and viral 
diversity globally and in individual patients. The speed and utility of 
these studies rely on rapid sharing of both materials and data. Global 
collaboration is essential for addressing questions on this global scale. 
In addition, it requires new talent to develop the tools and technol-
ogy necessary for the corresponding sophisticated data deposition 
and analysis. Thus, an enabling environment is necessary to foster 
collaboration and attract new talent to the field. Such an environment 
will include intra- and interdisciplinary collaborations, an integrated 
global network for population studies and agreed-upon mechanisms 
to share specimens and data from anywhere in the world.
recommendations
Create new and support existing “centers of excellence” to foster 
diverse intra- and interdisciplinary collaborations on a global scale. 
Interdisciplinary centers should be supported to attract scientists from 
other areas of immunology, from cell and molecular biology, and from 
physical sciences and mathematics. New talent and resources may be 
opment. Nine genetic subtypes (A,B,C,D,F,G,H,J,K) circulate in the 
epidemic and two recombinant forms (CRF01_AE and CRF02_AG) 
are also of major importance. Many other recombinant forms circulate 
at lower levels or in a more limited geographic range. The seemingly 
limitless capacity for tolerating genetic variation makes HIV one of 
the most challenging targets for coverage by vaccines (reviewed in23). 
The current focus of vaccine development is on a handful of clades or 
recombinant forms that infect large populations or wide geographic 
areas; in order of global distribution, these are clade C, CRF02_AG, 
clades A, B, D, and CRF01_AE.
Antibodies and variability. The envelope gp120 protein is the most 
variable part of the virus (>10% amino acid intraclade differences and 
>20% interclade differences). The five regions of hypervariability (V1-
V5) are under strong selective pressure by neutralizing antibodies, 
from which the virus rapidly escapes24. More conserved regions of 
the envelope are hidden from antibodies in the internal faces of the 
trimer, masked by glycosylation, or are conformationally labile. The 
membrane-proximal gp41 is less variable and contains sites that are 
conserved and recognized by neutralizing monoclonal antibodies with 
broad specificity (bNAbs)25. However, membrane lipid has an influ-
ence on binding of this type of antibody and, if targeted by a vaccine, 
may lead to autoreactivity with lipid antigens25,26.
An extensive search and analysis of HIV-1 envelope-specific mono-
clonal antibodies has led to isolation of novel bNAbs27. Unfortunately, 
it has not yet been possible to efficiently trigger this type of antibody 
through vaccination28, because the epitopes recognized by the bNAbs 
characterized to date are rarely seen by antibodies in vaccinated indi-
viduals. Nevertheless, the isolation of bNAbs has important implica-
tions for vaccine design29 - development of immunogens able to elicit 
bNAbs at high titer represents an actively pursued strategy to overcome 
HIV sequence and epitope variability.
T cell responses and virus variability. CD8+ T cell receptors are highly 
sensitive to amino acid changes in the targeted epitope: epitopes with 
single mutations are recognized by only a minority of T cell clones and 
double mutants are only rarely recognized30,31. The rapid selection of 
virus escape mutations by CD8+ T cells in acute HIV infection dramati-
cally illustrates the ease with which HIV can escape these responses32. 
Thus, trials that test candidate vaccines based on clades that differ to 
the ones that the trial population is exposed to are likely to fail.
The impact of HIV variability on vaccine design is manifest in two 
ways. First, the vaccine and the virus may mismatch, even within the 
same clade, to the extent that the vaccine-induced responses are inef-
fective. This factor may have contributed to the failure of the Merck 
Step trial vaccine33, which only elicited T cell responses to a median of 
three epitopes, of which only one was in gag, the most ‘protective’ pro-
tein in CTL recognition studies34. Second, vaccine-elicited responses 
may be easily evaded if the response focuses on a variable region of 
the virus. For development of a broadly efficacious vaccine, it will be 
important to elicit responses of considerable breadth, unlike the nar-
row responses that occur during acute natural infection and result in 
a cycle of selection and escape.
To overcome these problems, immune responses could be stimulated 
to all the common variants (for example, by using mosaic vaccines35), or 
to the most conserved regions of the virus proteome36. It is clear from 
the above considerations that HIV variability and its ability to escape 
both the humoral and T cell responses remain unresolved challenges. A 
better understanding of the fitness costs of escape, and the role of viral 
compensatory mutations, are therefore high priorities6,9,37.
Virus variability and innate immune responses. Not all selected 
mutations observed in acute HIV-1 infection can be explained by T 
cell escape, antibody escape or reversion to consensus (presumably 
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table 1.  summary of priorities and recommendations
priority 1. create enabling environments that foster innovative, collaborative, 
and global approaches
• Create new and support existing “centers of excellence” to foster diverse 
intra- and interdisciplinary collaborations on a global scale.
• Collect and share specimens and data on global host and viral diversity.
priority 2: understanding the role of host genetics in hIV vaccine research
• Ensure that the contributions of the host genome to variability in acquisi-
tion and disease phenotypes are considered in clinical trials and population 
cohorts.
• Complement human genetic studies with parallel investigation in NHP 
models.
priority 3: understand viral evolution, and exploit this information in vaccine 
development
• Establish, expand and coordinate large multidisciplinary efforts to study 
infected individuals during the earliest stage after infection through the first 
1-2 years.
• Use NHP models to dissect the earliest events after infection that are cur-
rently not accessible for studies in humans.
• Develop a multi-pronged approach, using a diversity of models and assays, 
to study relative impact of selective forces on viral evolution and constraints 
on viral genetic flexibility.
priority 4: defining how the interplay between viral and host diversity contrib-
utes to immune containment of the virus
• Develop novel assays to measure antiviral activity responsible for immune 
containment.
• Initiate population studies that address viral diversity in the context of host 
genetic environment.
• Prioritize and facilitate phase I trials that address host and virus diversity.
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for measuring viral fitness are needed to reflect the environment in 
which the virus replicates in vivo.
The dynamics of viral sequence changes in natural infection sug-
gest the immune response exerts its maximum impact on the virus 
during acute infection. The nature of the immune responses and the 
level of viral control and diversification at this stage likely determine 
the ultimate disease course. Current studies of acute infection have 
explored the transmission bottleneck and early immune responses 
(reviewed in38). These studies, with strong bioinformatics support, 
should be expanded to include larger numbers of patients from 
genetically-diverse populations with different contributing risk fac-
tors. Coordination through protocol and data sharing and the use of 
common analytical tools will be vital.
While detailed studies on breakthrough infections in human par-
ticipants in future HIV vaccine trials are invaluable, NHPs present 
the most convenient model to study how vaccine-induced responses 
influence the course of events early after infection. Studies in macaques 
challenged with SIV are crucial to understand early mucosal events, 
the mechanisms determining the bottleneck of the founder virus and 
the role of very early innate immune responses.
recommendations
Establish, expand and coordinate large multidisciplinary efforts to 
study infected individuals during the earliest stage after infection 
through the first 1-2 years. Whenever possible, these studies should 
include vaccine recipients who acquire HIV-1 infection.
Use NHP models to dissect the earliest events after infection that are 
currently not accessible for studies in humans. Use the NHP model to 
study viral diversification and to define drivers of viral evolution.
Develop a multi-pronged approach, using a diversity of models and 
assays, to study relative impact of selective forces on viral evolution 
and constraints on viral genetic flexibility. This approach should rely 
on accelerated efforts to develop and deploy new viral fitness assays 
and more complex mathematical models of virus evolution.
priority 4: defining how the interplay between viral and host 
diversity contributes to immune containment of the virus
How does the host genome influence the ability of immune responses 
to effectively deal with virus diversity? Half of all elite controllers carry 
the HLA B57 allele39, but not all B57 infected patients are elite control-
lers. We need to understand the mechanisms by which advantageous 
HLA types confer protection against the virus and whether this protec-
tion can be activated with vaccines in genetically diverse populations. 
Progress in this area requires answers to two key questions. First, we 
need to understand the competing influences for the virus between 
escape from host immune responses and the associated fitness costs. 
Second, the mechanisms responsible for immunodominance of T- and 
B-cell responses are not understood.
These questions can be answered in exploratory phase I studies 
that take into account both host and virus diversity. These studies 
should explore strategies to increase the strength, the breadth (num-
ber of epitopes) and the specific targeting of responses (immunodomi-
nance).
recommendations
Develop novel assays to measure antiviral activity responsible for 
immune containment.
Initiate population studies that address viral diversity in the context 
of host genetic environment.
Prioritize and facilitate phase I trials that address host and virus 
diversity.
found in emerging economies, like China and India, and in regions 
hardest hit by the HIV-1 epidemic. This talent should be engaged in 
international efforts through collaborations with existing centers in the 
developing world and nurtured by training and mentoring for young 
investigators. Strong scientific leadership in these centers is critical 
to address key questions in HIV vaccine research and development. 
Collaborations between clinicians, epidemiologists, local medical per-
sonnel, and laboratory scientists need to be well-directed and equally 
valued.
Collect and share specimens and data on global host and viral diver-
sity. Besides recruiting new talent, an enabling environment requires 
broad access to reagents, high-quality specimens and data from popu-
lation studies and unique cohorts. A major limitation in study of host 
and virus diversity is access to representative populations and adequate 
samples. There is a need for such studies in populations outside those 
infected with clade B and C viruses. Creation of a database of cohort 
studies worldwide, together with standardized protocols and proce-
dures, will be needed.
priority 2: understanding the role of host genetics in hIV 
vaccine research
New high-throughput genetic approaches have the potential to identify 
major genetic factors contributing to clinical outcome in HIV-1 infec-
tion. Ideally, every human gene that impacts on each mode of HIV 
transmission and disease outcome should be identified to improve our 
understanding of the mechanisms of protection. To accomplish this 
goal, investigated populations should include geographically-diverse 
regions and extreme phenotype cohorts, such as elite controllers, rapid 
progressors and exposed uninfected individuals.
Non-human primates (NHP) are valuable in defining the early 
events following mucosal infection, and testing novel vaccine concepts. 
Thus, the genetic structure of NHP and its impact on vaccination and 
infection needs further investigation.
recommendations
Ensure that the contributions of the host genome to variability in 
acquisition and disease phenotypes are considered in clinical trials and 
population cohorts. Complete genetic characterization of infected trial 
participants (vaccinated and placeboes) is important for understand-
ing the impact of host diversity on vaccine responses and the interplay 
between the genetics of the host and the virus. Epidemiological stud-
ies should use advanced statistical methods and sophisticated study 
designs that take into account genetics of the studied population.
Complement human genetic studies with parallel investigation in 
NHP models. The key role of the NHP model in HIV vaccine research 
makes it imperative to understand the contribution of genetics to vac-
cine-induced protective immune responses and the outcome of SIV 
infection.
priority 3: understand viral evolution, and exploit this 
information in vaccine development
Understanding the selective forces acting on viral populations and 
constrains on viral immune escape is central to developing an HIV-1 
vaccine. Efforts in this area should go beyond measurements of 
immune pressure by CTL and neutralizing antibodies to consider 
the effects of non-neutralizing antibodies, impact of diversity of 
target cells, contribution of long-lived latent pools, role of genetic 
drift, and many other potentially important factors. These analyses 
will require in vivo, in vitro and in silico models of viral replication, 
including mathematical modeling that takes into account structural 
and functional penalties of virus mutation. In particular, better assays 
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d. conclusIons
Host genetic diversity has major influences on the outcomes of both 
HIV-1 infection and host responses to infection. Vaccine strategies 
need to take this genetic diversity into account. Viral diversity needs 
to be understood in the context of all the selective forces acting on 
the virus at different stages of infection. Rational development of an 
effective vaccine will need to embrace all these issues.
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